** Shares of life science co PacBio PACB.O rise 8.8% to $1.30
** Co reports preliminary Q1 revenue of $36.9 million vs analysts' average estimate of $33.5 million, according to data compiled by LSEG
** Co plans to reduce its headcount and lower adjusted operating expense run-rate by $45 million to $50 million by year-end
** "Given the persistent uncertainty surrounding academic and NIH funding, along with the introduction of new tariffs, we are taking strategic steps to reduce spending," CEO Christian Henry says
** Up to last close, stock down 34.4% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.